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Lipid droplets (LDs) are dynamic neutral lipid storage organelles. Bersuker et al. employ an APEX2-based proximity labeling strategy to define highconfidence LD proteomes from human cells. They reveal a role for endoplasmic reticulum-associated degradation in controlling the levels of an LD protein identified here that regulates LD lipid composition.
INTRODUCTION
Lipid droplets (LDs) are conserved neutral lipid (e.g., triacylglycerol and sterols esters) storage organelles that are present in nearly all cells (Hashemi and Goodman, 2015; Pol et al., 2014; Walther and Farese, 2012) . Although the mechanisms of LD biogenesis are not well understood, emerging data suggest that LDs are formed de novo through deposition of neutral lipids between the leaflets of the ER, followed by vectorial budding of the nascent LD from the outer leaflet of the ER into the cytoplasm (Chen and Goodman, 2017) . The mature LD contains a neutral lipid core encircled by a phospholipid monolayer decorated with integral and peripheral proteins that regulate LD functions (Bersuker and Olzmann, 2017) . LDs are lipid storage depots that can be rapidly accessed to provide cells with fatty acids for energy production, membrane biosynthesis, and lipid signaling (Hashemi and Goodman, 2015; Pol et al., 2014; Walther and Farese, 2012) . In addition, LDs prevent lipotoxicity caused by free fatty acids and their flux into toxic lipid species (Koliwad et al., 2010; Listenberger et al., 2003; Nguyen et al., 2017; Senkal et al., 2017) . The accumulation of LDs in non-adipose tissues is a pathological feature of metabolic disease such as obesity, diabetes, and atherosclerosis (Greenberg et al., 2011; Krahmer et al., 2013a) . A role for LDs in the pathogenesis of metabolic diseases is further supported by the identification of mutations in LD-associated proteins that cause familial lipodystrophies and neutral lipid storage diseases (Greenberg et al., 2011; Krahmer et al., 2013a) .
The hydrophobic core of LDs is an energetically unfavorable environment for hydrophilic protein domains. Thus, proteins are absent from the LD core and are embedded within the bounding phospholipid monolayer through a variety of structural motifs, including hairpin-forming hydrophobic elements, short hydrophobic regions, amphipathic helices, and lipid anchors (Bersuker and Olzmann, 2017) . Proteins also associate peripherally with LDs by binding to proteins integrated into the LD membrane. LD functions are intrinsically connected to the composition of the LD proteome. For example, LD-associated acyltransferases such as GPAT4, AGPAT3, and DGAT2 regulate TAG synthesis and LD expansion during LD biogenesis (Wilfling et al., 2013) . Conversely, LD-associated lipases mediate TAG catabolism and LD degradation (Lass et al., 2011) . LD metabolism is also controlled by recruitment of proteins to LDs in response to changes in cellular metabolism; e.g., CCT1 (Krahmer et al., 2011) , GPAT4 (Wilfling et al., 2013) , and hormone-sensitive lipase (HSL) (Sztalryd et al., 2003) . Defining a comprehensive inventory of LD proteins, their functions, and their mechanisms of regulation is paramount for understanding the role of LDs in health and disease. Numerous studies have attempted to catalog the LD proteome through proteomic analysis of LD-enriched, biochemically isolated buoyant fractions (Table S1 ). The interpretation of these studies has been complicated by the presence of proteins from co-fractionating organelles and/or membrane fragments. Common false positives include ER and mitochondrial proteins whose spatial segregation from LDs (e.g., proteins in the ER lumen) or membrane-integrated motifs (e.g., polytopic proteins integrated into ER and mitochondrial bilayer membranes) prevent them from accessing the LD monolayer (Bersuker and Olzmann, 2017) . Thus, accurately defining the LD proteome and its mechanisms of regulation remains an outstanding challenge.
The limitations associated with proteomic analysis of biochemically purified organelles spurred the development of proximity labeling strategies to define organelle proteomes (Kim and Roux, 2016; Rees et al., 2015) . Engineered ascorbate peroxidase (APEX), and its more active version, APEX2 (Lam et al., 2015) , have been used to map the proteomes of the mitochondrial matrix (Rhee et al., 2013) , intermembrane space (Hung et al., 2014) , and outer membrane (Hung et al., 2017) , as well as the proteomes of the ER outer membrane (Hung et al., 2017) , the autophagosome lumen (Le Guerroué et al., 2017) , and the primary cilium (Mick et al., 2015) . In the presence of the APEX2 substrate biotin-phenol (also known as biotin-tyramide), a brief pulse of hydrogen peroxide (H 2 O 2 , <1 min) results in the APEX2-catalyzed generation of short-lived, membraneimpermeable biotin-phenoxyl radicals that form covalent adducts with electron-rich amino acids in proteins located within a 10-20 nm radius (Bendayan, 2001; Hung et al., 2014) . The irreversible conjugation of biotin enables the capture of labeled proteins for proteomic analysis. Labeling of proteins is performed in intact, living cells, thus preserving organelle architecture and minimizing post-lysis artifacts.
In this study, APEX2 targeted to LDs in two cell types labeled the vast majority of previously validated LD proteins and identified proteins whose localization on LDs was not previously established. Importantly, the high-confidence LD proteomes generated using LD-targeted APEX2 are free of common contaminating proteins. We further demonstrate the utility of LD-targeted APEX2 to examine LD proteome dynamics and discover that the composition of the LD proteome is in part regulated by ER-associated degradation (ERAD), a process that mediates ubiquitin-dependent protein quality and quantity control in the early secretory pathway (Olzmann et al., 2013a; Ruggiano et al., 2014; Stevenson et al., 2016) . These data provide an important LD proteomics resource (http://dropletproteome. org) and reveal a mechanism that regulates the composition of LD proteomes.
RESULTS

Generation and Characterization of LD-Targeted APEX2
To target APEX2 to the LD membrane, we generated osteosarcoma (U2OS) Flp-In cell lines that inducibly express V5-tagged APEX2 genetically fused to the C terminus of the perilipin family member PLIN2 (PLIN2-APEX2) and a mutant version of the lipase ATGL (ATGL*-APEX2) containing an inactivating S47A mutation that prevents ATGL-mediated lipolysis of LDs (Figure 1A) . Cells expressing a cytosolic version of APEX2 (Cyto-APEX2) were also generated to control for non-specific labeling of cytosolic proteins by LD-targeted APEX2. Incubation of cells with doxycycline induced expression of the APEX2 fusions and the addition of biotin-phenol/H 2 O 2 increased the levels of biotinylated proteins ( Figures 1B, S1A , and S1B), indicating that the APEX2 fusion proteins are catalytically active.
To confirm that the LD-targeted APEX2 proteins are recruited to LDs, the localization of V5-APEX2 fusions was determined after induction of LD biogenesis with oleate. Both PLIN2-APEX2 and ATGL*-APEX2 decorated the periphery of LDs labeled by the fluorescent fatty acid BODIPY-C12-568, indicating that APEX2 is recruited to the LD monolayer ( Figure 1C ). In contrast, Cyto-APEX2 was diffusely distributed throughout the cytoplasm and nucleoplasm ( Figure 1C ). Fluorescently labeled streptavidin stained the periphery of LDs in PLIN2-APEX2 and ATGL*-APEX2 cells treated with biotin-phenol/H 2 O 2 ( Figure 1D ), but not in the Cyto-APEX2 cells, indicating that LD-targeted APEX2 biotinylates proteins on the LD surface. To further verify that LDtargeted APEX2 biotinylates proteins on LDs, we analyzed the distribution of biotinylated proteins in LD-enriched buoyant fractions isolated by sucrose gradient centrifugation ( Figures  1E-1G ). PLIN2-APEX2 and ATGL*-APEX2 were not exclusively present in the buoyant fraction and, like Cyto-APEX2, biotinylated proteins in the cytosolic fractions ( Figures 1E-1G , fractions 2-5), and, to a lesser extent, proteins in the membrane fraction ( Figures 1E-1G , fraction P). Importantly, biotinylated proteins were only observed in LD-enriched buoyant fractions isolated from the PLIN2-APEX2 and ATGL*-APEX2 cells ( Figures  1E-1G , fraction BF). Together, these results demonstrate that LD-targeted APEX2 biotinylates proteins on LDs.
Identification of a High-Confidence LD Proteome
Non-specific labeling of cytosolic proteins has been reported in previous proteomics studies of organelles in which APEX2 was exposed to the cytosol (Hung et al., 2014 (Hung et al., , 2017 . This limitation was addressed by using ratiometric stable isotope labeling with amino acids in cell culture (SILAC) to subtract the cytosolic background (Hung et al., 2014 (Hung et al., , 2017 . However, this approach selects against proteins that localize to more than one cellular compartment. Given that several known LD proteins localize to LDs/ER (e.g., UBXD8, GPAT4, and AUP1) and LDs/cytosol (e.g., VCP, UBE2G2, and HSL), we chose to use subcellular fractionation in lieu of SILAC to separate the biotinylated proteins on LDs from those present in the cytosol and on other organelles ( Figure 2A ). Liquid chromatography-tandem mass spectrometry was used to determine the identity and abundance (i.e., normalized total spectral counts) of proteins isolated by affinity purification and of proteins in the total buoyant fraction. The proteins identified in the PLIN2-APEX2 samples (152 proteins) and ATGL*-APEX2 samples (192 proteins) represented a small subset of the proteins identified in the total buoyant fraction (1,227 proteins) (Figures 2B and 2C; Table S2 ), but the spectral counts from these two samples were highly correlated (R 2 = 0.76991) ( Figure 2D ). Fifty-two proteins were also identified in the Cyto-APEX2 samples, accounting for non-specific labeling by LDtargeted APEX2 ( Figure 2B ; Table S2 ). The buoyant fraction contained 44 proteins that were previously observed to localize to LDs by microscopy analyses of endogenous or tagged proteins ( Figure 2B ; Table S2 ), all of which were labeled by at least one of the LD-targeted APEX2 proteins (Figures 2B, S2A, and S2B; Table S2 ). The LD protein SPG20 (Eastman et al., 2009 ) was labeled by APEX2, but was not identified in the buoyant fraction ( Figure S2A ; (A) Illustration of the proximity labeling strategy to identify lipid droplets (LD) proteins. Cells stably expressing ATGL*-V5-APEX2, PLIN2-V5-APEX2, or Cyto-V5-APEX2 are treated with doxycycline (dox) for 48 hr to induce expression of LD-targeted or cytosolic APEX2 proteins, and then treated with oleate for 24 hr to induce formation of LDs. LD-targeted APEX2 covalently modifies proximal LD proteins with biotin upon addition of biotin-phenol and hydrogen peroxide (H 2 O 2 ). Biotinylated proteins are subsequently affinity purified and identified by mass spectrometry. (B) U2OS cells stably expressing cytosolic or LD-targeted APEX2 were treated with 0-100 ng/mL dox for 48 hr and biotin-phenol/H 2 O 2 . Total proteins from lysed cells were separated by SDS-PAGE and analyzed by blotting with fluorescently labeled streptavidin and antibodies against the V5 epitope tag. (C) U2OS cells stably expressing cytosolic or LD-targeted APEX2 were treated with 200 mM oleate and 1 mM BODIPY-C12-568 for 24 hr to induce formation of BODIPY-C12-568-positive LDs (red). Cells were imaged by fluorescence microscopy and the APEX2 fusion proteins were detected using antibodies against the V5 epitope tag (green). Magnified insets show cellular regions with LDs. Scale bars represent 10 mm. (D) U2OS cells stably expressing cytosolic or LD-targeted APEX2 incubated with 200 mM oleate for 24 hr were treated with biotin-phenol/H 2 O 2 and imaged by fluorescence microscopy using fluorescent streptavidin-568 (red) and antibodies against the V5-epitope tag (green). Scale bars represent 10 mm. (E-G) Lysates from U2OS cells stably expressing LD-targeted or cytosolic APEX2 were fractionated by sucrose gradient centrifugation. Proteins in individual fractions were separated by SDS-PAGE and analyzed by blotting with fluorescent streptavidin-568 and antibodies against the V5 epitope tag. See also Figure S1 ; Table S1 . Figure S1C for details). To define a highconfidence LD proteome, we set a threshold CS value that included >85% of previously validated LD proteins, yielding a high-confidence proteome consisting of 153 proteins ( Figure 2B ; Table S2 ). The abundant proteins in the buoyant fraction that were not labeled by PLIN2-APEX2 or ATGL*-APEX2 included many common contaminants identified in previous proteomic studies, including ER luminal proteins (disulfide isomerases PDIA1, PDIA3, and PDIA6), chaperones (GRP78, GRP94, and SerpinA1), and polytopic ER membrane proteins (CALR, CANX, and VAPA) (Figures 2E-2G and S2C; Table S2 ). Thus, the proximity labeling approach discriminates between proteins on LDs and contaminating proteins in the buoyant fraction.
Gene ontology-term analysis of high-confidence LD proteins showed enrichment of pathways that control TAG metabolism, lipid biosynthesis, and sterol biosynthesis ( Figure 2H ; Table S3 ). Other pathways included protein and vesicle-mediated transport, small GTPase signaling, oxidation-reduction processes, and membrane organization ( Figure 2H ; Table S3 ). To visualize functional relationships between LD proteins, high-confidence proteins were grouped into modules, and physical interactions between proteins were retrieved from the Bio-GRID database (Figure 3 ). The high-confidence LD proteome contained a group of previously validated LD regulatory scaffold proteins and TAG metabolism enzymes, including the perilipin family members (PLIN2, PLIN3, and PLIN4), acyl-coenzyme A (acyl-CoA) synthetases (ACSL3 and ACSL4), glycerol-3-phosphate acyltransferases (GPAT3 and GPAT4), lipases (PNPLA2, PNPLA3, and LIPE), and the PNPLA2 lipase regulator (ABHD5, also known as CGI-58). Another group within the metabolism-related module contained several enzymes from the cholesterol biosynthesis (SQLE, LSS, and NSDHL) and retinol metabolism (RDH10 and RDH11) pathways. Proteins that function in oxidation-reduction reactions (AIFM2, CYB5R3, HSDL1, and DHRS1) were also identified, the majority of which have not been validated as LD proteins. Surprisingly, half of all human Rab GTPases were present within the vesicular trafficking module, several of which (RAB1A, RAB7A, RAB8A, and RAB11B) were previously demonstrated to have functional roles on LDs. This result suggests that the large number of RAB GTPases identified in previous LD proteomics studies (Table S1 and Bartz et al., 2007; Liu et al., 2004 Liu et al., , 2007 are present on LDs. Another prominent module has functions related to the ubiquitin system and several of these proteins (FAF2, UBXN4, AUP1, UBE2G2, and VCP) form protein complexes on the ER membrane that function in degrading luminal and membrane ER proteins through the ERAD pathway (Christianson et al., 2011; Stevenson et al., 2016) . The identification of UBE2G2 and VCP, which associate with LDs by binding to their membrane-integrated adaptors AUP1 (Klemm et al., 2011; Spandl et al., 2011) and UBXD8 (Olzmann et al., 2013b; Suzuki et al., 2012) , respectively, demonstrates that LD-targeted APEX2 can identify peripherally associated LD proteins.
To examine if LD-targeted APEX2 identified new LD proteins, we fused GFP to the C terminus of 13 high-confidence proteins that have not been shown to localize to LDs. As expected, cytosolic (GFP) and ER-targeted (Sec61b-GFP) proteins were not recruited to LDs (Figure 4 ). In contrast, we found that 11/13 GFP-tagged high-confidence proteins decorated the periphery of LDs (Figure 4). Some of the fusion proteins were also present in the cytosol (AIFM2-GFP and PITPNB-GFP), reticular structures resembling ER (RDH11-GFP), or elongated perinuclear structures resembling Golgi (RAB1B-GFP) (Figure 4 ), indicating that our approach identifies LD proteins present in more than one cellular compartment. For the proteins that did not localize to LDs (ANXA7-GFP and CRACR2A-GFP), we cannot exclude the possibility that their localization on LDs was masked by high expression in the cytosol or disrupted by fusion to GFP. We also noted that the overexpression of several proteins (c18orf32-GFP, LSS-GFP, HSD17B7-GFP, SCCPDH-GFP, and ZFYVE1-GFP) resulted in increased LD abundance and/or clustering (Figure 4) , but the functional role of these proteins on LDs will require further investigation. These results indicate that LD-targeted APEX2 identifies new LD proteins that have potentially important functions in LD biology.
An Integrated U2OS and Huh7 High-Confidence LD Proteome LDs in different cell types have unique attributes (e.g., differences in size, regulatory mechanisms, or lipid composition) and express distinct LD proteins that specify these features. Liver is a metabolic organ that mediates the packaging and secretion of very low density lipoproteins, de novo lipogenesis, and recycling of lipoprotein remnants (Gluchowski et al., 2017) . The aberrant accumulation of LDs in the liver, or hepatic steatosis, is a feature of many metabolic diseases and a pathogenic hallmark of infection by the hepatitis C virus (Gluchowski et al., 2017) . Thus, the differences between U2OS and liver cells, as well as the physiological importance of LDs in liver function, led us to investigate the LD proteome in a liver-derived cell model. To map the liver LD proteome, we introduced the APEX2 proximity biotinylation system into the Huh7 human hepatocellular carcinoma cell line ( Figures S3A and S3B) , which has been extensively utilized to study hepatocyte function. LDs were more abundant in Huh7 than in U2OS cells, and exhibited a larger heterogeneity in size ( Figures 1C, S3C , and S3D). Similarly High-confidence LD proteins are grouped into functional modules based on GO analysis and UNIPROT functional annotations. Solid lines represent physical interactions within functional modules and transparent lines represent interactions between proteins in distinct modules, as annotated in Bio-GRID. The intensity of the blue color in a node indicates the confidence score. Nodes outlined in red represent proteins that have been previously validated to localize to LDs by microscopy.
to LD-targeted APEX2 in U2OS cells, PLIN2-APEX2 and ATGL*-APEX2, but not Cyto-APEX2, localized to LDs and biotinylated proteins in buoyant fractions ( Figures S3C-S3G ). Proteomic analyses identified 197 biotinylated proteins purified from PLIN2-APEX2 and 124 biotinylated proteins purified from ATGL*-APEX2 cells among 624 total proteins in the Huh7 buoyant fraction (Figures S4A-S4F ; Table S4 ). Despite the lower number of high-confidence LD proteins identified in Huh7 cells, all 37 previously validated proteins present in the Huh7 buoyant fraction were labeled by at least one version of LD-targeted APEX2 (Figures S5A and S5B ; Table S4 ). In addition, several validated LD proteins (e.g., CIDEB and MGLL) that were not identified in the buoyant fraction were labeled by LD-targeted APEX2 (Figures S5A and S5B ; Table S4 ), further supporting the ability of LD-targeted APEX2 to identify low-abundance LD proteins, while avoiding abundant contaminants (e.g., CALR, CANX, and HSPA5) (Figures S4D-S4F and S5C; Table S4 ).
When comparing the high-confidence LD proteomes from U2OS and Huh7 cells, we found 63 shared high-confidence LD proteins (Figures S6A and S6B) . These proteins included 9 of the 11 new proteins validated in U2OS cells (Figures 4 and 5) . CIDEB, which belongs to a family of CIDE proteins that mediate LD fusion (Gao et al., 2017) , was only identified in Huh7 cells, consistent with the larger LDs in this cell line. The absence of other CIDE proteins (CIDEA and CIDEC) indicates that CIDEB is the dominant member of this protein family in Huh7 cells and is consistent with the expression pattern of CIDE family genes in mouse tissues ( Figure S6C ). Interestingly, we identified SQSTM1 (also known as p62) as a Huh7-specific LD protein. SQSTM1 mediates selective autophagy by binding ubiquitinconjugated cargo through its ubiquitin-associated domain and autophagosome membranes conjugated to LC3 through its LC3-interacting region motifs (Johansen and Lamark, 2011) , thus physically linking cargo to autophagic machinery. Since LDs in Huh7 cells and mouse liver are degraded by a selective autophagy pathway known as lipophagy (Li et al., 2016; Singh et al., 2009) , our data raise the possibility that SQSTM1 may be an adaptor that targets LDs for degradation by lipophagy.
Quantitative Analysis of LD Proteome Composition Following Inhibition of VCP
The temporal resolution afforded by the APEX2 proximity labeling system could enable the study of LD proteome remodeling by allowing capture of ''snapshots'' of the LD proteome under different conditions, such as after pharmacological treatments or changes in metabolic state. To examine this possibility, we employed LD-targeted APEX2 to investigate the role of ubiquitin-dependent protein degradation pathways in regulating the composition of the LD proteome.
Several proteins in the ubiquitin module ( Figure 5 ) are present in macromolecular ER ubiquitination complexes that mediate the degradation of ER proteins in the ERAD pathway (Christianson et al., 2011) . These components could regulate the composition of the LD proteome through two non-mutually exclusive mechanisms: (1) through the degradation of LD proteins by canonical ERAD pathways as they transit between the ER and LDs, or (2) through the degradation of LD proteins by ubiquitination machinery on LDs. We anticipated that degradation of LD proteins through either mechanism would require the AAA ATPase VCP, which in ERAD is essential for the extraction of ubiquitinated proteins from the ER membrane for degradation by cytosolic 26S proteasomes (Meyer et al., 2012; Olzmann et al., 2013a) . To investigate if VCP regulates the stability of LD proteins, and thus the steady-state levels of proteins on LDs, we performed ratiometric SILAC analysis of biotinylated LD proteins purified from ATGL*-APEX2 control cells (light) and cells treated with the VCP inhibitor CB5083 (heavy) To et al., 2017) (Figure 6A ). While the levels of the majority of highconfidence proteins were unaffected by CB5083 treatment, levels of c18orf32 increased by 1.8-fold ( Figure 6B ; Table S5 ).
C18orf32 is an uncharacterized 76 amino acid protein that contains a predicted hydrophobic N-terminal domain and a C-terminal unstructured region. C18orf32 was identified as a high-confidence LD protein in both U2OS and Huh7 cells (Figure 5) . In the absence of oleate, GFP-tagged c18orf32 was present in the ER ( Figure S7A ). Addition of oleate caused a fraction of c18orf32-GFP to redistribute to LDs (Figures S7A and S7E) . To confirm the localization of c18orf32 on LDs, we performed immunofluorescence microscopy using a polyclonal antibody that recognizes endogenous c18orf32. Endogenous c18orf32 was distributed in puncta most apparent at the periphery of LD clusters, confirming that the localization of c18orf32 at LDs is not an artifact of overexpression ( Figure 6C ). As expected, small interfering RNA-mediated depletion of c18orf32 abolished the LDlocalized puncta ( Figure 6C ). Consistent with the localization of c18orf32 on LDs and the ER, immunoblot analysis of subcellular fractions identified a single major band that resolved at 12 kDa in size, and was present only in the pellet and buoyant fractions ( Figure 6D ). Genetic deletion of c18orf32 using CRISPR/Cas9 resulted in the disappearance of the 12 kDa immunoreactive band, indicating that the antibody recognizes c18orf32 ( Figure S7B ). To address the possibility that localization of c18orf32 at the periphery of LDs was due to wrapping of c18orf32-positive ER around LDs, we generated cell lines expressing an S-tagged version of c18orf32 (c18orf32-S) and determined the extent of colocalization of c18orf32-S with the LD protein PLIN2 and the ER protein calnexin. C18orf32-S exhibited strong colocalization with PLIN2 ( Figure S7C ), but not calnexin ( Figure S7D ), around LDs. In addition, we employed stimulated emission depletion (STED) microscopy to generate high resolution (40 nm) images of c18orf32-S ( Figure 6E ). C18orf32-S formed discrete puncta that decorated the LD periphery ( Figure 6E ) and exhibited more colocalization with PLIN2 than with calnexin around LDs ( Figures 6F and 6G ). Although we observed calnexinpositive ER juxtaposed to LDs, STED imaging indicated that c18orf32-S and calnexin signals are discrete ( Figure 6F ). A) SILAC strategy to identify VCP-regulated LD proteins. ATGL*-V5-APEX2 cells were cultured in light or heavy lysine-containing SILAC medium and incubated with 200 mM oleate for 24 hr. U2OS cells were subsequently treated with vehicle (light) or 5 mM VCP inhibitor CB5083 (heavy) for 6 hr. Cells were incubated with biotin-phenol/H 2 O 2 , biotinylated buoyant fractions from light-and heavy-labeled cells were combined, and light/heavy-labeled biotinylated proteins were affinity purified for identification by mass spectrometry. (B) The heavy-to-light fold change ratio of biotinylated proteins purified from cells treated with CB5083 and vehicle as depicted in (A). (C) U2OS cells were transfected with control or c18orf32-targeting small interfering RNA (siRNA) for 48 hr, incubated with 200 mM oleate for 24 hr, and analyzed by SDS-PAGE or fluorescence microscopy using antibodies against c18orf32 (red) and the neutral lipid dye BODIPY 493/503 (green) to stain LDs. Magnified insets show cellular regions with LDs. Scale bars represent 10 mm. (D) U2OS cells were incubated with 200 mM oleate for 24 hr. Cellular homogenates were fractionated by sucrose gradient centrifugation, and proteins in individual fractions were separated by SDS-PAGE and immunoblotted with antibodies against c18orf32 and PLIN2. P, pellet; BF, buoyant fraction. (E) U2OS cells stably expressing c18orf32-S were incubated with 200 mM oleate and fixed cells were sequentially imaged by confocal and STED microscopy using the neutral lipid dye BODIPY 493/503 and antibody against S-tag. In both examples shown, LDs were only visualized using confocal microscopy. Scale bars represent 500 nm. (F) U2OS cells stably expressing c18orf32-S were incubated with 200 mM oleate and fixed cells were sequentially imaged by confocal microscopy to visualize BODIPY 493/503-positive LDs and STED microscopy to visualize c18orf32-S and PLIN2 or calnexin. Scale bars represent 1 mm. (G) The degree of colocalization between c18orf32-S and PLIN2 or calnexin in (F) was assessed by recording the Pearson's correlation coefficient across multiple regions (n = 16) per condition. Values represent mean ± SD. Asterisk indicates a significant difference (*p < 0.001).
(legend continued on next page)
To determine which region of c18orf32 targets the protein to LDs, we generated GFP fusions of c18orf32 mutants lacking the hydrophobic N-terminal region (D1-37) or the C-terminal region (D38-76) ( Figure 6H ). Similar to full-length c18orf32-GFP, c18orf32(D38-76)-GFP exhibited a reticular and punctate distribution in the ER under basal conditions and localized to LDs in oleate-treated cells ( Figure 6I ). In contrast, the c18orf32(D1-37)-GFP mutant was diffusely distributed throughout the cell and was absent from LDs ( Figure 6I ). These data indicate that the N-terminal hydrophobic domain is necessary and sufficient for recruitment of c18orf32 to ER and LDs.
We noted that c18orf32-GFP was also present in highly dynamic puncta in proximity to reticular ER ( Figures 6I and 6J) . These puncta were reminiscent of nascent LDs that bud from the ER during LD biogenesis Wang et al., 2016) . In agreement with this possibility, time-lapse microscopy revealed that c18orf32-GFP puncta colocalized with emerging BODIPY-C12-568-positive LDs ( Figure 6K ). We further explored if c18orf32-GFP is recruited to nascent LDs by co-expressing markers of early LDs. HPos-mOrange, a fusion of mOrange to the hydrophobic region of the LD protein ALDI and the positively charged region of Caveolin-1, is recruited into puncta in the ER that mark sites of LD biogenesis in cells starved in Hank's buffered salt solution (HBSS) . C18or32-GFP completely colocalized with HPos-mOrange and was recruited into HBSS-induced, HPos-positive puncta ( Figure 6L ). Under these conditions, c18orf32-GFP also exhibited partial colocalization with puncta marked by LiveDrop ( Figure 6M ), a fusion of mCherry to the hairpin region of GPAT4 . Together, these findings indicate that c18orf32 is an ER protein that traffics to emerging LDs.
c18orf32 Is Degraded by a gp78-and derlin-1-Dependent ERAD Pathway Our proteomics results ( Figure 6B ; Table S5) suggest that VCP regulates the levels of c18orf32 on LDs. To determine if VCP regulates the stability of c18orf32, we measured the degradation kinetics of c18orf32 after inhibiting protein synthesis with the translation inhibitor emetine. The levels of c18orf32 decreased by 50% after 6 hr of emetine treatment ( Figures 7A-7C ), indicating that a fraction of c18orf32 is constitutively degraded. Addition of CB5083 blocked the degradation of c18orf32, similar to its effect on the degradation of the ERAD substrate, core-glycosylated CD147(C.G.) Tyler et al., 2012) (Figures  7A-7C) . Furthermore, even a modest depletion of VCP by RNAi markedly increased the steady-state levels and stability of c18orf32 ( Figure 7E ). To assess if the degradation of c18orf32 requires ubiquitin conjugation and proteolysis by the 26S proteasome, we measured the degradation kinetics of c18orf32 in cells treated with MLN-7243, an inhibitor of the E1 ubiquitin-activating enzyme, and with MG132, an inhibitor of the 26S proteasome. Treatment with MLN-7243 or MG132 prevented the degradation of c18orf32 to the same extent as CB5083 (Figures 7A-7C ). LD induction with oleate did not affect the kinetics of c18orf32 degradation ( Figures 7A and 7D ), indicating that LD induction is not sufficient to stabilize c18orf32. However, since a significant fraction of c18rf32 remains in the ER in oleate-treated cells ( Figures 6D, 6I , and S7D), it is possible that the smaller, LD-associated pool of c18orf32 is stabilized under these conditions. Thus, c18orf32 is constitutively degraded through a pathway that requires ubiquitin conjugation, VCP, and the proteasome.
To determine if c18orf32 is degraded by ERAD, or alternatively, by ubiquitin/VCP-dependent machinery on LDs, we analyzed the proteins that interact with S-tagged c18orf32. We confirmed that the degradation kinetics of c18orf32-S, but not of the cytosolic mutant c18orf32(D1-37)-S, were similar to that of endogenous c18orf32 and were impaired by depletion of VCP ( Figures S7F and S7G ). Quantitative proteomic analyses showed that c18orf32-S (Table S6) co-purified erlin-1 and derlin-1, two well-defined components of the ERAD pathway ( Figure 7F ). Treatment with CB5083 also increased the levels of ubiquitin and VCP that co-purified with c18orf32-S ( Figure 7F ), consistent with impaired extraction of ubiquitinated c18orf32-S by bound VCP. Analysis of c18orf32-S interactors did not identify E3 ubiquitin ligases that mediate the degradation of c18orf32-S. To identify a potential E3 ligase for c18orf32, we conducted a candidate screen using HEK293 cells in which we deleted known E3 ligases of the ERAD pathway, including RNF5, Hrd1, and gp78. Deletion of gp78, but not deletion of Hrd1 or RNF5, impaired the degradation of c18orf32 ( Figure 7G ). In contrast, CD147(C.G.) was stabilized by the deletion of its cognate E3 ligase, Hrd1 (Tyler et al., 2012) (Figure 7G ). Affinity purification revealed that c18orf32-S interacts with both derlin-1 and gp78 ( Figure 7H ). The levels of gp78 that co-purified with c18orf32-S increased with CB5083 treatment (Figure 7H ), suggesting that inhibition of VCP traps c18orf32 in complex with an ERAD dislocation apparatus containing gp78 and derlin-1. Indeed, we found that c18orf32 was stabilized to the same extent in gp78 knockout (KO) and derlin-1 KO cells (Figures 7I and 7J) . We next examined if deletion of gp78, like inhibition of VCP, increased levels of (H) Illustration of c18orf32-GFP truncation mutants lacking the N-terminal hydrophobic region (HR) (D1-37) or the C-terminal region (D38-76). (I) U2OS cells stably expressing full-length c18orf32-GFP or truncation mutants c18orf32(D38-76)-GFP and c18orf32(D1-37)-GFP were treated with dox for 48 hr and incubated in the presence and absence of 200 mM oleate supplemented with 1 mM BODIPY-C12-568 for 24 hr. Cells incubated in the absence of oleate were treated with 0.5 mM BODIPY-C12-568 to label LDs. Live cells were imaged by fluorescence microscopy. Magnified insets show cellular regions with LDs. Scale bars represent 10 mm. (J) U2OS cells stably expressing c18orf32-GFP were treated with dox for 48 hr and imaged by time-lapse fluorescence microscopy. C18orf32-GFP puncta are indicated by arrowheads. Time stamp indicates elapsed time in seconds after start of imaging. Scale bars represent 2.5 mm in the montage. (K) U2OS cells stably expressing c18orf32-GFP were treated with dox for 48 hr and subsequently treated with 1 mM BODIPY-C12-568. Colocalized c18orf32-GFP and BODIPY-C12-568 puncta are indicated by arrowheads. Time stamp indicates elapsed time in minutes after addition of BODIPY-C12-568. Scale bars represent 2.5 mm in the montage. (L and M) U2OS cells stably expressing c18orf32-GFP were transiently transfected with HPos-mOrange or LiveDrop for 48 hr and treated with dox for 24 hr. Cells were subsequently incubated in HBSS medium and imaged by time-lapse fluorescence microscopy. Colocalized c18orf32-GFP and HPos-mOrange (L) or LiveDrop (M) puncta are indicated by arrowheads. Time stamp indicates time elapsed in minutes after addition of HBSS. Scale bars represent 2.5 mm in the montage. See also Figure S7 ; Table S5 . Proteins from cell lysates were separated by SDS-PAGE and analyzed by blotting with antibodies against c18orf32, CD147, and tubulin. C.G., core-glycosylated; mat., mature.
(B) U2OS cells were treated with 75 mM emetine and vehicle, 10 mM MG132, or 10 mM MLN-7243 as indicated. Proteins from cell lysates were separated by SDS-PAGE and analyzed by blotting with antibodies against c18orf32, CD147, and tubulin. C.G., core-glycosylated; deglyc., deglycosylated; mat., mature.
(legend continued on next page) c18orf32 on LDs. Levels of c18orf32 in ER-enriched pellet fractions from gp78 KO cells were modestly increased (1.4-fold) relative to control cells ( Figure 7K ). The increase in c18orf32 levels in LD-enriched buoyant fractions from gp78 KO cells was significantly greater (2.3-fold) ( Figure 7K ). Thus, these results indicate that ERAD regulates the levels of c18orf32 on LDs.
To investigate potential functions of c18orf32 on LDs, such as in LD biogenesis or turnover, we determined the size distribution of LDs in c18orf32 null cells that were either treated with oleate to induce formation of new LDs or starved in glucose-free medium after oleate treatment to promote degradation of existing LDs. In control experiments, transient depletion of ACSL3 by RNAi inhibited formation of large LDs in oleate-treated cells, consistent with the critical function of ACSL3 in neutral lipid synthesis ( Figures S7H and S7J) . Conversely, depletion of ATGL resulted in higher LD numbers in oleate-treated cells and reduced lipolytic degradation of LDs in starved cells (Figures S7I and S7J) . Deletion of c18orf32 did not significantly alter the LD distribution after oleate treatment or starvation ( Figure S7K ). Similarly, overexpression of c18orf32-S did not have an overt effect on LDs ( Figure S7L ), suggesting that neither deletion nor overexpression of c18orf32 affects LD dynamics in a manner that can be observed by light microscopy. To determine if loss of c18orf32 affects other LD features, such as lipid composition, lipids extracted from buoyant fractions were analyzed by single-reaction monitoring-based liquid chromatography-mass spectrometry lipidomic profiling (Table S7) . Although the levels of most lipids (e.g., triacylglycerol) were unaltered, loss of c18orf32 resulted in altered levels of several lipid species, including monoacylglycerol (C18:0 MAG), monoacylglycerol ether (C16:0e/C2:0 MAGe), and stearic acid (C18:0) ( Figure 7L ; Table S7 ). The decrease in MAG and increase in stearic acid raises the possibility that c18orf32 may regulate HSL, which generates MAG and free fatty acids during the lipolytic degradation of diacylglycerol. Although additional studies are required to examine the potential regulation of HSL by c18orf32, these results indicate that LD-associated c18orf32 modulates LD lipid composition.
DISCUSSION
LDs are regulators of lipid and energy metabolism that are central to the pathogenesis of human metabolic diseases. Attempts to define the LD proteome through proteomic analysis of biochemically isolated buoyant fractions have been plagued by the presence of contaminating proteins. Recent studies combined fractionation of LDs with protein correlation profiling to yield more specific LD proteomes in Drosophila S2 cells (Krahmer et al., 2013b) and yeast (Currie et al., 2014) , but potentially failed to detect proteins that localize to multiple cellular compartments. Refined fractionation approaches have further increased the purity of LD preparations, but have been unable to completely separate LDs from other associated organelles . Thus, the inability to accurately define LD proteomes has remained an obstacle to understanding the role of LD-associated proteins in LD biology. In this study, we implemented a proximity labeling strategy to generate high-confidence LD proteomic maps in two human cell lines and established the utility of this approach to study LD proteome dynamics.
Our results indicate that proximity labeling proteomics identifies a complete and specific LD proteome. LD-targeted APEX2 labeled all proteins in the total buoyant faction that were previously shown to localize to LDs, and identified previously validated LD proteins (e.g., SPG20, CIDEB, and MGLL) that were not detected in the LD-enriched buoyant fraction. The method also (C and D) The percentage of c18orf32 remaining (relative to time = 0 hr) was quantified by densitometry analysis of immunoblots in (A and B). Data points represent mean ± SEM (n R 3 independent experiments). (E) U2OS cells were transfected with scrambled control siRNA or siRNA targeting VCP for 72 hr and subsequently treated with emetine as indicated. Proteins from cell lysates were separated by SDS-PAGE and analyzed by blotting with antibodies against c18orf32, VCP, tubulin, and CD147. (F) U2OS cells stably expressing c18orf32(WT)-S or parental cells were cultured in SILAC medium and treated with dox for 48 hr. c18orf32(WT)-S cells were subsequently treated with vehicle or 5 mM CB5083 for 6 hr. Proteins from cell lysates were combined in equal ratios, c18orf32(WT)-S was affinity purified using S-protein-conjugated agarose beads, and interacting proteins were identified by mass spectrometry. For each identified protein, the x axis represents fold change abundance ratio of proteins associated with c18orf32(WT)-S relative to parental cells, and the y axis represent fold change abundance ratio of proteins associated with c18orf32(WT)-S in cells treated with CB5083 relative to cells treated with vehicle. Background proteins are indicated as gray data points and interactors (above a SILAC ratio of 1.5) are indicated as blue data points. (G) Control HEK293 cells or cells lacking Hrd1, RNF5, or gp78 were treated with emetine as indicated. Proteins from whole-cell lysates were separated by SDS-PAGE and analyzed by blotting with antibodies against c18orf32, tubulin, CD147, Hrd1, RNF5, and gp78. (H) Control cells or U2OS cells stably expressing c18orf32-S were treated with vehicle or 5 mM CB5083 for 6 hr as indicated. C18orf32-S was affinity purified, and the cell lysates (input, 0.2%, w/w) and eluted proteins (AP) were analyzed by immunoblotting with antibodies against gp78, derlin-1, Hrd1, and c18orf32-S. Antibodies against GAPDH, calnexin, and tubulin were included to control for loading and affinity purification. (I) Control HEK293 cells or cells lacking derlin-1 (upper panel) or gp78 (lower panel) were treated with emetine as indicated. Proteins from whole-cell lysates were separated by SDS-PAGE and analyzed by immunoblotting with antibodies against c18orf32, derlin-1, CD147, and tubulin. (J) The percentage of c18orf32 remaining (relative to time = 0 hr) was quantified by densitometry analysis of immunoblots in (I). Data points represent mean ± SEM (n R 3 independent experiments). (K) Control HEK293 cells or cells lacking gp78 were treated with 200 mM oleate for 24 hr and pellet and buoyant fractions were purified by density gradient centrifugation. Levels of c18orf32 in pellet and buoyant fractions were determined by SDS-PAGE/immunoblot and normalized to the levels of calnexin and UBXD8, respectively. Data points represent mean ± SEM (n R 3 independent experiments). (L) Lipids from buoyant fractions (n = 4) isolated from clonal, c18orf32-null cells or cas9-expressing control cells were extracted and analyzed by mass spectrometry. Levels of all lipid species were compared with those present in control cells. Significantly altered lipids are shown. Asterisk indicates a significant difference (*p < 0.001). (M) Model depicting the c18orf32 degradation pathway. C18orf32 traffics between the ER membrane and LDs. Levels of c18orf32 on LDs are controlled by an ERAD pathway that includes derlin-1, gp78, and the AAA ATPase VCP. See also Figure S7 ; Tables S6 and S7. identified a significant number of new proteins on LDs, many of which were identified in both U2OS and Huh7 cells. These proteins may constitute functionally important LD machinery and therefore warrant further investigation. Importantly, LD-targeted APEX2 effectively excluded abundant non-LD proteins that are frequently identified in LD proteomic studies and comprise the vast majority of proteins present in buoyant fractions.
Some limitations have been ascribed to proximity labeling approaches. For example, proteins that are buried within macromolecular complexes may not be accessible for labeling. While this may be a limitation in our study, LD-targeted APEX2 fusions labeled all known LD proteins in the buoyant fraction, suggesting that APEX2 labeling achieves high coverage of the LD proteome. Recent APEX2 studies using ratiometric SILAC to subtract cytosolic background labeling reported that some proteins that localize to more than one cellular compartment may be filtered out, contributing to the incomplete coverage of organelle proteomes: 53% coverage of the outer mitochondrial membrane proteome (Hung et al., 2017) , 44% coverage of the outer ER membrane proteome (Hung et al., 2017) , and 67% coverage of the mitochondrial intermembrane space proteome (Hung et al., 2014) . In light of this limitation, we used a subcellular fractionation step to isolate LD proteins from labeled cytosolic proteins. Although it remains possible that some peripherally associated LD proteins were lost during the fractionation procedure, we successfully identified peripheral proteins that are known to have both LD and cytosolic localization (e.g., VCP [Meyer et al., 2012; Olzmann et al., 2013b; Peters et al., 1990] , HSL [Egan et al., 1992; Sztalryd et al., 2003] , and UBE2G2 [Klemm et al., 2011; Spandl et al., 2011] ).
We used LD-targeted APEX2 in combination with quantitative proteomics to advance our understanding of how the composition of the LD proteome is regulated. Protein degradation by the ubiquitin-proteasome system is a fundamental mechanism of protein quantity control (Komander and Rape, 2012) . Although several LD proteins are degraded by the proteasome (Bersuker and Olzmann, 2017) , the mechanisms and machinery that target these proteins for degradation are mostly unknown. Comparative proteomic analyses of LD proteomes identified c18orf32 as an ER-LD protein whose levels on LDs are regulated by ERAD. Our results support a model ( Figure 7M ) in which c18orf32, like many other LD proteins, is inserted into the ER during or following translation, and then laterally diffuses from the ER bilayer into the monolayer of emerging LDs. ERAD regulates the levels of c18orf32 in the ER, and thus determines the amount of c18orf32 that is available to traffic to LDs ( Figure 7M ). This model is in strong agreement with a recent study in yeast (Ruggiano et al., 2016) , which demonstrated that the ERAD E3 ligase Doa10p, the E2 ubiquitin-conjugating enzyme Ubc7p (yeast ortholog of UBE2G2), and the AAA ATPase Cdc48p (yeast ortholog of VCP) regulated the levels of several proteins on LDs by mediating their degradation in the ER. That study (Ruggiano et al., 2016 ) and our findings demonstrate that ERAD is a general mechanism that regulates the abundance of select proteins on LDs. Consistent with this possibility, gp78 and VCP regulate the stability of the ER-LD protein DGAT2 (Choi et al., 2014) , although it is unclear if this mechanism of regulation determines the levels of DGAT2 on LDs. In addition to regulating the stability of LD proteins initially inserted into the ER, ERAD may also degrade LD proteins that traffic from LDs to the ER through ER-LD membrane bridges (Wilfling et al., 2013) . Further studies will be required to determine the overall contribution and importance of ERAD in regulating the composition of the LD proteome under different metabolic conditions. Together, these findings establish the utility of proximity labeling in investigating LD proteome dynamics and provide a foundation for future studies that will investigate how the LD proteome is remodeled in response to metabolic signals in diverse models of cellular metabolism.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Live cells were stained with BODIPY 493/503 and Hoechst, and >100 positions were automatically acquired in a grid pattern for each experimental condition using a 60X objective. The resulting BODIPY 493/503 images were loaded into a custom package written in MATLAB (MathWorks) that uses a built-in algorithm to detect circular objects (LDs), a recursive segmentation algorithm to quantify nuclei number and a data analyzer to bin, normalize and compile the data of LD size distributions into histograms. All histograms were normalized by the number of nuclei to determine mean LD size distribution per cell. The MATLAB programs and supporting documentation can be found at http://dropletproteome.org.
Quantification of Immunoblotting
All immunoblots were visualized using a LI-COR imager (LI-COR Biosciences). Band density was quantified using ImageJ software and the mean ± SEM was determined from three independent experiments.
DATA AND SOFTWARE AVAILABILITY
The accession number for the proteomics data reported in this paper is PRIDE database : PXD007695.
